Voss Capital LP Boosts Stock Position in Actuate Therapeutics, Inc. $ACTU

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP raised its position in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 157.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 142,381 shares of the company's stock after purchasing an additional 87,135 shares during the quarter. Voss Capital LP owned 0.73% of Actuate Therapeutics worth $964,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC purchased a new stake in Actuate Therapeutics during the 1st quarter valued at about $70,000. Sfmg LLC purchased a new stake in shares of Actuate Therapeutics in the first quarter worth about $74,000. Sigma Planning Corp boosted its stake in shares of Actuate Therapeutics by 47.3% in the first quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock worth $160,000 after buying an additional 7,600 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Actuate Therapeutics in the fourth quarter worth about $84,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Actuate Therapeutics in the fourth quarter worth about $130,000.

Analyst Upgrades and Downgrades

ACTU has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Actuate Therapeutics in a research note on Monday. Craig Hallum initiated coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 target price on the stock.

Insider Buying and Selling

In other Actuate Therapeutics news, Director Leslie W. Kreis purchased 71,428 shares of Actuate Therapeutics stock in a transaction that occurred on Friday, June 27th. The stock was bought at an average price of $7.00 per share, with a total value of $499,996.00. Following the acquisition, the director owned 196,428 shares of the company's stock, valued at $1,374,996. This trade represents a 57.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Aaron G.L. Fletcher purchased 71,428 shares of Actuate Therapeutics stock in a transaction that occurred on Friday, June 27th. The stock was acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the acquisition, the director directly owned 196,428 shares in the company, valued at $1,374,996. This trade represents a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 214,284 shares of company stock valued at $1,499,988. 69.34% of the stock is owned by company insiders.

Actuate Therapeutics Stock Performance

Shares of ACTU opened at $8.25 on Tuesday. Actuate Therapeutics, Inc. has a 52 week low of $5.47 and a 52 week high of $11.99. The stock's 50-day moving average price is $7.11 and its 200-day moving average price is $7.96.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Actuate Therapeutics Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

Want to see what other hedge funds are holding ACTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.